Pharmacological effect Dutahair
A cure for the treatment of benign prostatic hyperplasia. Suppresses the activity of the 5α-reductase 1 and 2 isoenzymes, responsible for the conversion of testosterone to 5α-dihydrotestosterone. Dihydrotestosterone is the main androgen responsible for the hyperplasia of the glandular tissue of the prostate.
The maximum effect of dutastéride on the decrease in concentration of dihydrotestosterone depends on the dose and is observed after 1-2 weeks. After the start of treatment. After 1 and 2 weeks. Dutastéride at the dose of 0,5 mg / day, the mean dihydrotestosterone concentration in the serum is reduced by 85% and 90%.
Dutahair helps reduce the size of the prostate gland, improves urination and reduces the risk of acute urine retention and the need for surgical treatment.
Indications of use
Treatment of benign prostatic hyperplasia.
Dutahair dosing regimen
For adult men, including elderly patients, the recommended oral dose is 500 μg 1 times daily. The treatment should last at least 6 months.
- Dutahair is contraindicated in patients with hypersensitivity to this drug, other 5-alpha-reductase inhibitors, or any of the ingredients of this drug.
- Dutasteride (Avodart) is contraindicated in women, children and adolescents.
- Dutastéride is contraindicated in patients with severe hepatic impairment.